Sagefield Capital’s Cidara Therapeutics CDTX Stock Holding History

Sagefield Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-57,075	Closed	-$12.6M	–	117
2025 Q4	$12.6M	Buy	+57,075	New	+$9.22M	1.07%	33

Sagefield Capital's CDTX Position: Q1 2026 in Review

Sagefield Capital sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 57,075 shares — an estimated $12.6M sold.

Sagefield Capital first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $12.6M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Sagefield Capital reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Sagefield Capital sold 57,075 Cidara Therapeutics shares in Q1 2026, an estimated $12.6M.
Sagefield Capital first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Sagefield Capital's Cidara Therapeutics position peaked at $12.6M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Sagefield Capital's 13F filing for Q1 2026, filed 15 May 2026.